FY2024 Earnings Forecast for Humana Issued By Zacks Research

Humana Inc. (NYSE:HUM - Free Report) - Equities researchers at Zacks Research upped their FY2024 EPS estimates for Humana in a report issued on Wednesday, November 13th. Zacks Research analyst D. Chatterjee now anticipates that the insurance provider will post earnings per share of $16.04 for the year, up from their prior estimate of $16.01. The consensus estimate for Humana's current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Humana's Q1 2025 earnings at $6.37 EPS and Q2 2025 earnings at $6.25 EPS.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%.

A number of other brokerages have also recently commented on HUM. KeyCorp started coverage on Humana in a research note on Friday, October 11th. They set a "sector weight" rating on the stock. Barclays boosted their price target on Humana from $250.00 to $253.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. increased their price objective on shares of Humana from $332.00 to $396.00 and gave the company a "neutral" rating in a research report on Wednesday, August 21st. Truist Financial dropped their price objective on shares of Humana from $400.00 to $260.00 and set a "hold" rating on the stock in a research note on Friday, October 11th. Finally, Piper Sandler downgraded shares of Humana from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $392.00 to $274.00 in a research note on Thursday, October 3rd. Twenty equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $315.86.

Humana Stock Down 2.6 %

Shares of NYSE:HUM traded down $7.47 during midday trading on Friday, hitting $275.67. 1,841,500 shares of the company's stock traded hands, compared to its average volume of 1,875,008. The firm's fifty day moving average price is $283.00 and its two-hundred day moving average price is $331.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana has a twelve month low of $213.31 and a twelve month high of $527.18. The company has a market cap of $33.19 billion, a PE ratio of 24.47, a P/E/G ratio of 2.29 and a beta of 0.52.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.28%. The ex-dividend date is Tuesday, December 31st. Humana's dividend payout ratio (DPR) is presently 31.36%.

Institutional Trading of Humana

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Swedbank AB raised its stake in Humana by 3.0% during the 3rd quarter. Swedbank AB now owns 105,976 shares of the insurance provider's stock valued at $33,567,000 after acquiring an additional 3,085 shares in the last quarter. Heritage Oak Wealth Advisors LLC acquired a new stake in shares of Humana during the second quarter worth $3,456,000. Mandatum Life Insurance Co Ltd boosted its position in shares of Humana by 115.4% in the 3rd quarter. Mandatum Life Insurance Co Ltd now owns 14,000 shares of the insurance provider's stock valued at $4,434,000 after purchasing an additional 7,500 shares during the period. APG Asset Management US Inc. lifted its stake in Humana by 3.0% during the second quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider's stock valued at $25,274,000 after buying an additional 1,955 shares in the last quarter. Finally, Cetera Advisors LLC boosted its holdings in shares of Humana by 472.1% in the first quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider's stock worth $3,501,000 after buying an additional 8,333 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.